Image credit: Canva
Multiple myeloma is a tumor in which malignant plasma cells accumulate in the bone marrow; it can cause organ damage and does not have a cure. A clinical trial led by Elizabeth M. Hill, M.D., Assistant Research Physician in the Lymphoid Malignancies Branch, is researching a combination drug treatment to try and prevent or slow down developing multiple myeloma and its associated organ damage. The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact the NCI Medical Oncology Referral Office at ncimo_referrals@nih.gov or (240) 760-6050.
Clinicaltrials.gov identifier: NCT04933539
Official Title: A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.